Clinical-scale 10-day TCR-T cell manufacturing using IL-2/7/15 and TGF-β promotes early memory and tissue-resident-like phenotypes and robust antitumor activity in vitro - Summary - MDSpire
Advertisement
Clinical-scale 10-day TCR-T cell manufacturing using IL-2/7/15 and TGF-β promotes early memory and tissue-resident-like phenotypes and robust antitumor activity in vitro
To establish a swift, clinical-scale methodology for producing TCR-T cells with enhanced memory and tissue-resident characteristics for therapeutic use.
Key Findings:
CKT-derived TCR-T cells showed increased early memory and tissue-resident phenotypes compared to IL-2 produced cells.
Enhanced production of effector cytokines (IFN-γ, TNF, GZMB) and improved cytotoxicity against cancer cell lines were observed.
Clinical-scale production yielded 3.30 and 6.15 x 10^9 total cells with similar characteristics to small-scale experiments.
Interpretation:
The innovative 10-day production protocol enhances the generation of TCR-T cells with favorable memory and tissue residency markers, potentially improving the efficacy of adoptive cell therapy.
Limitations:
The study primarily focuses on in vitro results; clinical efficacy remains to be validated in patient trials, and the limited sample size may restrict the applicability of the findings to broader patient populations.
Conclusion:
The novel TCR-T cell production method using IL-2, IL-7, IL-15, and TGF-β yields cells with enhanced characteristics that may significantly improve the effectiveness of adoptive cell therapy in clinical settings.
by Yi-Ping Shih, Stephan Drokin, Olivia Burke, Huayu Huang, Amy Leung, Marco Bravo-Manriquez, Myungkyu Jang, Marina S. Syrkina, Laura Julian, Nelson Sanjuan, Eric Tran
A systematic review and meta-analysis found that early time-of-day immunotherapy was associated with improved survival outcomes in patients with advanced cancers, with the association appearing to be ...
In the final analysis of the phase III EORTC 1333/PEACE-3 trial, with a median follow-up of 58 months, the addition of radium-223 to the androgen receptor inhibitor enzalutamide significantly prolonge...
Each year, globally, about 400,000 children and adolescents aged between 0 and 19 years are diagnosed with cancer; over 100,000 die from the disease, with most of those cases, over 80%, and deaths occ...
